Search research articles
Contact Us
Filters
Showing results (141-150 of 159) with videos related to
Page
of 16
Sort By:
Journal for Immunotherapy of Cancer
|
August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.
Nature Cancer
|
February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
JCO Precision Oncology
|
August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab
Alberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Nature Immunology
|
July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy
Giselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
NPJ Precision Oncology
|
February 13, 2026
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab
Eric Y Stutheit-Zhao, Yongqi Zhong, Collin A Melton, et al.
Nature Communications
|
August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
S Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Eclinicalmedicine
|
October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable
Christina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
Journal for Immunotherapy of Cancer
|
October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
Marc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Nature Communications
|
June 24, 2022
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
John Hilton, Karen Gelmon, Philippe L Bedard, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 159) with videos related to
Sort By:
Page
of 16
Journal for Immunotherapy of Cancer
|
August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.
Nature Cancer
|
February 5, 2022
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V Bratman, S Y Cindy Yang, Marco A J Iafolla, et al.
JCO Precision Oncology
|
August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab
Alberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
Nature Immunology
|
July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy
Giselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
NPJ Precision Oncology
|
February 13, 2026
Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab
Eric Y Stutheit-Zhao, Yongqi Zhong, Collin A Melton, et al.
Nature Communications
|
August 27, 2021
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
S Y Cindy Yang, Scott C Lien, Ben X Wang, et al.
Eclinicalmedicine
|
October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable
Christina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
Journal for Immunotherapy of Cancer
|
October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
Marc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Nature Communications
|
June 24, 2022
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
John Hilton, Karen Gelmon, Philippe L Bedard, et al.
Page
of 16